217 related articles for article (PubMed ID: 27338091)
21. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
22. Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.
Mastorci K; Muraro E; Pasini E; Furlan C; Sigalotti L; Cinco M; Dolcetti R; Fratta E
PLoS One; 2016; 11(4):e0153823. PubMed ID: 27123851
[TBL] [Abstract][Full Text] [Related]
23. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
25. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.
Babosova O; Kapralova K; Raskova Kafkova L; Korinek V; Divoky V; Prchal JT; Lanikova L
J Cell Mol Med; 2019 Nov; 23(11):7785-7795. PubMed ID: 31517438
[TBL] [Abstract][Full Text] [Related]
26. Flipping the cyclin D1 switch in mantle cell lymphoma.
Hasanali Z; Sharma K; Epner E
Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
[TBL] [Abstract][Full Text] [Related]
27. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen R; Chubb S; Cheng T; Hawtin RE; Gandhi V; Plunkett W
Cancer Res; 2010 Aug; 70(16):6587-97. PubMed ID: 20663900
[TBL] [Abstract][Full Text] [Related]
28. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
[TBL] [Abstract][Full Text] [Related]
29. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
30. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma.
Krieger S; Gauduchon J; Roussel M; Troussard X; Sola B
BMC Cancer; 2006 Oct; 6():238. PubMed ID: 17022831
[TBL] [Abstract][Full Text] [Related]
31. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
Kawamata N; Chen J; Koeffler HP
Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
[TBL] [Abstract][Full Text] [Related]
32. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
34. Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.
Knapp CM; He J; Lister J; Whitehead KA
Exp Biol Med (Maywood); 2016 May; 241(9):1007-13. PubMed ID: 27022142
[TBL] [Abstract][Full Text] [Related]
35. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
Jares P; Colomer D; Campo E
Nat Rev Cancer; 2007 Oct; 7(10):750-62. PubMed ID: 17891190
[TBL] [Abstract][Full Text] [Related]
36. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.
Weinstein S; Emmanuel R; Jacobi AM; Abraham A; Behlke MA; Sprague AG; Novobrantseva TI; Nagler A; Peer D
PLoS One; 2012; 7(8):e43343. PubMed ID: 22905260
[TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.
Katz SG; Labelle JL; Meng H; Valeriano RP; Fisher JK; Sun H; Rodig SJ; Kleinstein SH; Walensky LD
Blood; 2014 Feb; 123(6):884-93. PubMed ID: 24352880
[TBL] [Abstract][Full Text] [Related]
38. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
[TBL] [Abstract][Full Text] [Related]
39. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
